Biome Australia's Q1 FY25 Revenue Guidance

Biome Australia Limited (ASX:BIO) has forecasted that the sales revenue for the first quarter of the fiscal year 2025 is expected to exceed $4.0m, following a strong start to the September quarter. This projection indicates a new record quarter for sales revenue, surpassing the previous quarter's record of $3.8m in Q4 FY24.

Executive Commentary on Q1 FY25 Revenue Guidance

The company is pleased to announce the anticipated record-breaking sales revenue for the first quarter of fiscal year 2025. This forecast reflects the strong performance in the September quarter and demonstrates our commitment to delivering innovative, evidence-based live biotherapeutics and complementary medicines. We remain focused on improving health outcomes and accessibility to our products, both locally and internationally.

Summary of Q1 FY25 Revenue Guidance

Biome Australia Limited (ASX:BIO) has projected a significant increase in sales revenue for the first quarter of fiscal year 2025, expecting it to surpass $4.0m. The company's dedication to developing and commercializing innovative live biotherapeutics and complementary medicines supported by clinical research is evident in this forecast. With a focus on improving health outcomes and accessibility, Biome aims to continue its growth trajectory and make a positive impact on global health concerns.